AIM. To assess the therapy outcomes in pediatric patients with acute myeloid leukemias (AMLs) as well as to identify the most important poor prognostic factors and predictors of treatment efficacy. MATERIALS & METHODS. The retrospective analysis includes 35 newly diagnosed AML patients treated at the Moscow Regional Oncology Dispensary from 2018 to 2025. On diagnosis date, the age range was 0 to 17 years (median 7 years). Therapy (standardized induction and consolidation blocks, targeted drugs if needed, and allogeneic hematopoietic stem cell transplantation [allo-HSCT] in first remission) was administered in accordance with risk groups and obligatory monitoring of minimal residual disease (MRD). Clinical and laboratory features, cytogenetic and molecular markers (FLT3-ITD, NPM1, and CEBPA) as well as MRD were assessed after 1–2 courses of induction therapy. The distribution of FAB types was as follows: M7 in 6 (17.1 %), M1 in 5 (14.3 %), M4 in 5 (14.3 %), M5 in 4 (11.4 %), M5a in 4 (11.4 %), and M2 in 4 (11.4 %) cases; other types were detected in 7 (20 %) cases in total. Risk stratification identified 20 (57.1 %) high-, 12 (34.3 %) intermediate-, and 3 (8.6 %) standard-risk patients. RESULTS. At the time of this publication, 21 (60 %) patients are alive, and 14 (40 %) patients have died. The 3-year overall survival was 60 %, and event-free survival (EFS) was 41 %. In the studied cohort of AML patients, early MRD-negative status appeared to be the main predictor of favorable outcome: with MRD ≥ 0.1 % as early as after the first control examination (25.7 % of patients), the number of events significantly increased and long-term rates decreased, whereas achieving MRD-negative status at the end points went hand in hand with the formation of a pronounced plateau on the EFS curve. Clinical and cytogenetic high-risk parameters (FLT3-ITD mutation, hyperleukocytosis at the start, and extramedullary lesions) were associated with earlier unfavorable outcomes and required treatment escalation. The strategy of incorporating allo-HSCT into first-line therapy proved to have outstanding clinical efficacy for high-risk patients and those with MRD persistence. CONCLUSION. The results obtained are consistent with multi-center data on pediatric protocols of AML treatment. This study demonstrated that the risk-adapted therapy taking into account molecular genetic features of the tumor clone as well as MRD monitoring with the routing of patients to allo-HSCT if needed in first complete remission improve long-term survival rates in pediatric AML patients.